David Bouchey
Stock Analyst at Aegis Capital
(n/a)
# 4,378
Out of 4,789 analysts
6
Total ratings
n/a
Success rate
-57.68%
Average return
Main Sectors:
Stocks Rated by David Bouchey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SBFM Sunshine Biopharma | Reiterates: Buy | $15 | $2.08 | +621.15% | 2 | Dec 5, 2024 | |
| STSS Sharps Technology | Initiates: Buy | $352 | $0.03 | +1,289,277.29% | 1 | May 9, 2023 | |
| IINN Inspira Technologies Oxy B.H.N. | Maintains: Buy | $10 → $13 | $0.64 | +1,926.82% | 1 | Jan 25, 2023 | |
| RMTI Rockwell Medical | Downgrades: Outperform | $121 | $1.08 | +11,103.70% | 2 | Oct 19, 2018 |
Sunshine Biopharma
Dec 5, 2024
Reiterates: Buy
Price Target: $15
Current: $2.08
Upside: +621.15%
Sharps Technology
May 9, 2023
Initiates: Buy
Price Target: $352
Current: $0.03
Upside: +1,289,277.29%
Inspira Technologies Oxy B.H.N.
Jan 25, 2023
Maintains: Buy
Price Target: $10 → $13
Current: $0.64
Upside: +1,926.82%
Rockwell Medical
Oct 19, 2018
Downgrades: Outperform
Price Target: $121
Current: $1.08
Upside: +11,103.70%